Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. [electronic resource]
Producer: 20160412Description: 1763-70 p. digitalISSN:- 1029-2403
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Anemia -- chemically induced
- Area Under Curve
- Diarrhea -- chemically induced
- Drug Resistance, Neoplasm
- Exanthema -- chemically induced
- Female
- Humans
- Lymphoma -- drug therapy
- MAP Kinase Signaling System -- drug effects
- Male
- Metabolic Clearance Rate
- Middle Aged
- Nausea -- chemically induced
- Neoplasm Recurrence, Local
- Phosphoinositide-3 Kinase Inhibitors
- Quinoxalines -- adverse effects
- Remission Induction
- Sulfonamides -- adverse effects
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.